ALK and non-small cell lung carcinoma: The epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and c-ros oncogene 1 (ROS1) etc., are current molecular biomarkers that directly impact clinical therapy strategies for NSCLC [3].